1
|
Faris M, Bostancı HE, Özcan İ, Öztürk M, Koçyiğit ÜM, Erdoğan T, Tahtaci H. Imidazole-Derived Alkyl and Aryl Ethers: Synthesis, Characterization, In Vitro Anticancer and Antioxidant Activities, Carbonic Anhydrase I-II Inhibition Properties, and In Silico Studies. ACS OMEGA 2024; 9:20937-20956. [PMID: 38764643 PMCID: PMC11097166 DOI: 10.1021/acsomega.4c00028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 04/16/2024] [Accepted: 04/23/2024] [Indexed: 05/21/2024]
Abstract
Imidazole derivatives display extensive applications in pharmaceutical chemistry and have been investigated as bioactive compounds for medicinal chemistry. In this study, besides the starting materials (3a-c and 4a-c), synthesis, characterization, and biological activity studies were conducted on a total of 18 compounds, nine of which are known and the other nine are original. The compounds investigated in the study are a series of alkyl (7-15) and aryl (16-24) ether derivatives bearing substituted phenyl and imidazole rings, which were characterized using various methods including 1H NMR, 13C NMR, FT-IR analysis, elemental analysis, and mass spectroscopy. Computer-aided drug design studies have been carried out to predict the biological activities of compounds. Besides DFT calculations, the binding affinities of the compounds to EGFR, VEGFR2, FGFR1, HSP90, hCA I, and hCA II were investigated. Additionally, drug-likeness and ADME analyses were performed on the compounds. Anticancer, antioxidant, and enzyme inhibition activity tests were performed in biological activity studies on the synthesized compounds. Among the synthesized compounds, compounds 17 and 19-24 generally exhibited inhibition profiles against the widespread cytosolic hCA I isozyme with IC50 values ranging from 4.13 to 15.67 nM and cytosolic hCA II isozyme with IC50 values ranging from 5.65 to 14.84 nM. L929 (mouse fibroblast cell line) was used as the control healthy cell line, and MCF7 (breast cancer), C6 (rat glioblastoma), and HT-29 (colon cancer) cells were used in cell culture studies as cancer cell lines. Before the study on cancer cells, all compounds were examined on healthy cells, and their cytotoxicity was determined. As a result of these data, studies continued with six compounds determined to be nontoxic. On cancerous cells, it was determined that compounds 3a, 3b, 4a, 4b, 4c, and 7 had cytotoxic effects on both colon cancer and brain tumors. It was found that compound 3b had a more toxic effect than cisplatin on the glioma cell line with an IC50 value of 10.721 ± 0.38 μM, and compound 3a had a more toxic effect on the colon cancer cell line with an IC50 value of 20.88 ± 1.02 μM. However, it was determined that the same compounds did not have a statistically significant effect on breast cancer. Flow cytometry studies also showed that when the IC50 dose of compound 3b was applied to the C6 cell line, the cells tended to early and late apoptosis. Additionally, it has been shown by flow cytometry that the cell cycle stops in the G0/G1 phase. A similar effect was observed in the colon cancer cell line with compound 3a. Compound 3b caused early and late apoptosis of the colon cancer cell line with the applied IC50 dose and stopped the cell cycle in the G0/G1 phase. Finally, the FRAP method studied all synthesized compounds' antioxidant effects. According to the measured antioxidant power results, it was determined that no compound had a more effective reducing power than vitamin E.
Collapse
Affiliation(s)
- Mays Faris
- Department
of Chemistry, Faculty of Science, Karabuk
University, 78050 Karabuk, Türkiye
| | - Hayrani Eren Bostancı
- Department
of Biochemistry Sivas, Faculty of Pharmacy, Sivas Cumhuriyet University, 58010 Sivas, Türkiye
| | - İbrahim Özcan
- Department
of Chemistry, Faculty of Science, Karabuk
University, 78050 Karabuk, Türkiye
| | - Mustafa Öztürk
- Sivas
Vocational School of Technical Sciences, Sivas Cumhuriyet University, 58010 Sivas, Türkiye
| | - Ümit Muhammed Koçyiğit
- Department
of Biochemistry Sivas, Faculty of Pharmacy, Sivas Cumhuriyet University, 58010 Sivas, Türkiye
| | - Taner Erdoğan
- Kocaeli
Vocational School, Department of Chemistry and Chemical Processing
Technologies, Kocaeli University, 41140 Kocaeli, Türkiye
| | - Hakan Tahtaci
- Department
of Chemistry, Faculty of Science, Karabuk
University, 78050 Karabuk, Türkiye
| |
Collapse
|
2
|
Mathada BS, Basha NJ, Javeed M, Karunakar P, Venkatesulu A, Erappa K, Varsha A. Novel pyrimidines as COX-2 selective inhibitors: synthesis, DFT analysis, molecular docking and dynamic simulation studies. J Biomol Struct Dyn 2024; 42:1751-1764. [PMID: 37102863 DOI: 10.1080/07391102.2023.2202248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 04/08/2023] [Indexed: 04/28/2023]
Abstract
Pyrimidine and its derivatives are associated with varieties of biological properties. Therefore, we herein reported the synthesis of four novel pyrimidines (2, 3, and 4a, b) derivatives. The structure of these molecules is confirmed by spectroscopic methods such as IR, NMR, and Mass analysis. The electronic behavior of synthesized compounds 4a, b and in silico drug design 4 c, d was explained by Density Functional Theory estimations at the DFT/B3LYP level via 6-31 G++ (d, p) replicates the structure and geometry. All the synthesized compounds were screened for their in vitro COX-1 and COX-2 inhibitory activity compared to standards Celecoxib and Ibuprofen. Compounds 3 and 4a afforded excellent COX-1 and COX-2 inhibitory activities at IC50 = 5.50 and 5.05 μM against COX-1, 0.85 and 0.65 μM against COX-2, respectively. The standard drugs Celecoxib and Ibuprofen showed inhibitory activity at IC50 = 6.34 and 3.1 μM against COX-1, 0.56 and 1.2 μM against COX-2, respectively. Further, these compounds showed high potential docking with SARS-CoV-2 Omicron protease & COX-2 and predicted drug-likeness for the pyrimidine analogs by using Molinspiration. The protein stability, fluctuations of APO-protein, protein-ligand complexes were investigated through Molecular Dynamics simulations studies using Desmond Maestro 11.3 and potential lead molecules were identified.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
| | - N Jeelan Basha
- Department of Chemistry, Indian Academy Degree College-Autonomous, Bengaluru, Karnataka, India
| | - Mohammad Javeed
- P. G. Department and Research Studies in Chemistry, Nrupatunga University, Bengaluru, Karnataka, India
| | - Prashantha Karunakar
- Department of Biotechnology, Dayananda Sagar College of Engineering, Bengaluru, Karnataka, India
| | - Adavala Venkatesulu
- Department of Post Graduate Studies & Research Centre in Physics, Govt. First Grade College, Hoskote, Karnataka, India
| | - Krishnakanth Erappa
- Department of Post Graduate Studies & Research Centre in Physics, Govt. First Grade College, Hoskote, Karnataka, India
| | - A Varsha
- Department of Biotechnology, PES University, Bengaluru, Karnataka, India
| |
Collapse
|
3
|
Johnson TO, Adeyemi OE, Adegboyega AE, Olomu SA, Enokela F, Ibrahim S, Gwantu B, Afolayan B, Stephen K, Eseola AO, Plass W, Adeyemi OS. Elucidation of the anti-plasmodial activity of novel imidazole and oxazole compounds through computational and in vivo experimental approaches. J Biomol Struct Dyn 2023; 41:9013-9021. [PMID: 36310100 DOI: 10.1080/07391102.2022.2139761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 10/19/2022] [Indexed: 11/06/2022]
Abstract
The development of resistance to conventional antimalarial therapies, along with the unfavorable impact of the COVID-19 pandemic on the global malaria fight, necessitates a greater focus on the search for more effective antimalarial drugs. Targeting a specific enzyme of the malaria parasite to alter its metabolic pathways is a reliable technique for finding antimalarial drug candidates. In this study, we used an in silico technique to test four novel imidazoles and an oxazole derivative for inhibitory potential against Plasmodium lactate dehydrogenase (pLDH), a unique glycolytic enzyme necessary for parasite survival and energy production. The promising imidazole compounds and the oxazole derivative were then tested for anti-plasmodial efficacy in Plasmodium berghei-infected mice. With a binding energy of -6.593 kcal/mol, IM-3 had the best docking score against pLDH, which is close to that of NADH (-6.758 kcal/mol) and greater than that of chloroquine (-3.917 kcal/mol). The test compounds occupied the enzyme's NADH binding site, with IM-3 forming four hydrogen bonds with Thr-101, Pro-246, His-195 and Asn-140. Infected mice treatment with IM-3, IM-4 and OX-1 exhibited significantly reduced parasitemia over a four-day treatment period when compared to the infected untreated animals. At 5, 10 and 20 mg/kg, IM-3 demonstrated the highest anti-plasmodial activity, suppressing parasitemia by 86.13, 97.71 and 94.11%, respectively. PCV levels were restored by IM-3 and IM-4, and the three selected compounds reduced the lipid peroxidation induced by P. berghei infection in mice. Thus, these compounds may be considered for further development as antimalarial medicines.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
| | | | | | - Segun Afolabi Olomu
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Festus Enokela
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Sherifat Ibrahim
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Bernard Gwantu
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Bukola Afolayan
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Kamo Stephen
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Jos, Jos, Nigeria
| | - Abiodun Omokehinde Eseola
- Department of Chemical Sciences, Redeemer's University, Ede, Nigeria
- Institute of Inorganic and Analytical Chemistry, Friedrich-Schiller-Universität Jena, Jena, Germany
| | - Winfried Plass
- Institute of Inorganic and Analytical Chemistry, Friedrich-Schiller-Universität Jena, Jena, Germany
| | - Oluyomi Stephen Adeyemi
- Landmark University SDG 3 (Good Health & Well-being Research Group), Landmark University, Nigeria
- Department of Biochemistry, Medicinal Biochemistry and Toxicology Laboratory, Landmark University, Nigeria
| |
Collapse
|
4
|
Ahmed NM, Youns MM, Soltan MK, Said AM. Design, Synthesis, Molecular Modeling and Antitumor Evaluation of Novel Indolyl-Pyrimidine Derivatives with EGFR Inhibitory Activity. Molecules 2021; 26:molecules26071838. [PMID: 33805918 PMCID: PMC8037142 DOI: 10.3390/molecules26071838] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 03/19/2021] [Accepted: 03/20/2021] [Indexed: 01/15/2023] Open
Abstract
Scaffolds hybridization is a well-known drug design strategy for antitumor agents. Herein, series of novel indolyl-pyrimidine hybrids were synthesized and evaluated in vitro and in vivo for their antitumor activity. The in vitro antiproliferative activity of all compounds was obtained against MCF-7, HepG2, and HCT-116 cancer cell lines, as well as against WI38 normal cells using the resazurin assay. Compounds 1-4 showed broad spectrum cytotoxic activity against all these cancer cell lines compared to normal cells. Compound 4g showed potent antiproliferative activity against these cell lines (IC50 = 5.1, 5.02, and 6.6 μM, respectively) comparable to the standard treatment (5-FU and erlotinib). In addition, the most promising group of compounds was further evaluated for their in vivo antitumor efficacy against EAC tumor bearing mice. Notably, compound 4g showed the most potent in vivo antitumor activity. The most active compounds were evaluated for their EGFR inhibitory (range 53-79%) activity. Compound 4g was found to be the most active compound against EGFR (IC50 = 0.25 µM) showing equipotency as the reference treatment (erlotinib). Molecular modeling study was performed on compound 4g revealed a proper binding of this compound inside the EGFR active site comparable to erlotinib. The data suggest that compound 4g could be used as a potential anticancer agent.
Collapse
Affiliation(s)
- Naglaa M. Ahmed
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ein-Helwan, Helwan, Cairo 11795, Egypt;
| | - Mahmoud M. Youns
- Biochemistry Department, Faculty of Pharmacy, Helwan University, Ein-Helwan, Helwan, Cairo 11795, Egypt;
- Oman College of Health Sciences, Muscat 123, Oman;
| | - Moustafa K. Soltan
- Oman College of Health Sciences, Muscat 123, Oman;
- Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
| | - Ahmed M. Said
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ein-Helwan, Helwan, Cairo 11795, Egypt;
- Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA
- Correspondence: ; Tel.: +1-716-907-5016
| |
Collapse
|
5
|
Plasmodium falciparum Knockout for the GPCR-Like PfSR25 Receptor Displays Greater Susceptibility to 1,2,3-Triazole Compounds That Block Malaria Parasite Development. Biomolecules 2020; 10:biom10081197. [PMID: 32824696 PMCID: PMC7465636 DOI: 10.3390/biom10081197] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2020] [Revised: 08/13/2020] [Accepted: 08/15/2020] [Indexed: 01/05/2023] Open
Abstract
The search for new compounds with antimalarial activity is urgent, as resistance to ones in the classical drug, has already been described in more than one continent. Compounds derived from 1,2,3-triazoles are effective against parasites and bacteria. Here, we evaluated the potential antimalarial activity against the human malaria parasite Plasmodium falciparum in a culture of fifty-four triazole compounds derived from 1H-and 2H-1,2,3-triazole. We identified thirty-one compounds with potential antimalarial activity at concentrations in the micromolar order (µM) and IC50 values ranging from 2.80 µM (9) to 29.27 µM (21). Then, we selected some of these compounds to perform the same tests on the PfSR25- strain (knockout for P. falciparum G-protein coupled receptor-like, SR25). Our experiences with the PfSR25- strain showed that both compounds with higher antimalarial activity for the 3D7 strain and those with less activity resulted in lower IC50 values for the knockout strain. The cytotoxicity of the compounds was evaluated in human renal embryonic cells (HEK 293), using MTT assays. This demonstrated that the compounds with the highest activity (9, 13, 19, 22, 24, 29), showed no toxicity at the tested concentrations.
Collapse
|